Aperio Receives FDA Clearance for ER and PR Image Analysis Applications

Digital Pathology Leader Adds Third FDA Clearance for Digital Pathology in Breast Cancer

Press release today out of Aperio clears the way for their customers to perform image analysis on the trio of immunohistochemistry used routinely in breast carcinoma. 

"The addition of FDA cleared ER/PR image analysis applications to our previously cleared applications for HER2 underscores our commitment to provide clinicians and breast cancer patients with the most comprehensive entire-slide quantitative image analysis panel available anywhere," stated Dirk Soenksen, CEO of Aperio. "Aimed with these clearances, our customers can now take full advantage of our new digital IHC software to optimize their workflow and streamline reporting, while enjoying the benefits of quantitative image analysis."